Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · VanEck

VanEck Biotech ETF (BBH)

Ticker BBH · · Holdings as of Jun 30, 2026

Expense ratio
0.35%$35/yr per $10k
5-yr return
+2.7%annualized
1-yr return
+21.2%as of Dec 2025
Net assets
$395.6Mall share classes
Holdings
25

Bottom line

Is BBH a good fund? The bottom line

BBH is a managed technology sector ETF from VanEck.

It charges 0.35% — about $35 a year on every $10,000 invested, cheaper than 90% of technology sector funds we track.

It returned +21.2% over one year, +2.7% a year over five years, +4.5% a year over ten (as of Dec 31, 2025, per its prospectus).

With $396 million in net assets and 25 holdings, its largest position is Amgen Inc (15.2%) and the top 10 make up 70.3% of the portfolio.

The closest lower-cost alternative we found is IBBQ (0.19%, 59% top-holdings overlap).

What stands out

  • Low cost: cheaper than 90% of technology sector peers

What to watch

  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 70.3% of assets

Updated Nov 19, 2026

What BBH invests in

VanEck Biotech ETF (the Fund) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (the Biotech Index or the Index).

The Fund normally invests at least 80% of its total assets in securities that comprise the Funds benchmark index. For purposes of this policy, the term assets means net assets plus the amount of any borrowings for investment purposes. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. To be initially eligible for the Biotech Index, companies must generate at least 50% of their revenues from biotechnology. Biotechnology includes companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment (excluding pharmacies). Of the largest 50 stocks in the biotechnology industry…

From the fund's prospectus (filed Jan 27, 2026).

BBH performance

Fund calendar-year total returns, 2016–2025 2016: −15.0%; 2017: +16.6%; 2018: −10.2%; 2019: +25.8%; 2020: +22.1%; 2021: +11.8%; 2022: −15.1%; 2023: +3.9%; 2024: −4.4%; 2025: +21.2% −15% 2016 +17% 2017 −10% 2018 +26% 2019 +22% 2020 +12% 2021 −15% 2022 +4% 2023 −4% 2024 +21% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
BBH+21.2%+2.7%+4.5%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full BBH performance history →

What BBH costs

On a $10,000 investment, BBH's 0.35% expense ratio costs about $35 a year. The prospectus estimates $443 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full BBH fee table →

BBH top 10 holdings

#Holding% of fund
1Amgen Inc15.25%
2Gilead Sciences Inc12.79%
3Vertex Pharmaceuticals Inc9.10%
4Regeneron Pharmaceuticals Inc6.21%
5Revolution Medicines Inc5.27%
6Argenx SE4.97%
7Natera Inc4.92%
8IQVIA Holdings Inc4.31%
9Alnylam Pharmaceuticals Inc3.83%
10Biogen Inc3.63%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 70.3% of the fund. See all top 25 holdings and asset mix →

Alternatives to BBH

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
InvescoIBBQ Invesco Nasdaq Biotechnology ETF0.19%59% Compare
iSharesIBB iShares Biotechnology ETF0.44%66% Compare

More funds like BBH →

BBH FAQ

What is the expense ratio of BBH?
BBH's expense ratio is 0.35%, which works out to about $35 a year for every $10,000 invested. The prospectus estimates total costs of $443 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is BBH a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 90% of technology sector peers; 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 70.3% of assets. This is general information, not personalized advice.
What does BBH hold?
BBH's largest holdings are Amgen Inc (15.2%), Gilead Sciences Inc (12.8%), Vertex Pharmaceuticals Inc (9.1%), Regeneron Pharmaceuticals Inc (6.2%), Revolution Medicines Inc (5.3%). It holds 25 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is BBH's 5-year return?
BBH returned +2.7% a year over the five years ending Dec 31, 2025, and +4.5% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to BBH?
IBBQ (Invesco Nasdaq Biotechnology ETF) overlaps about 59% with BBH and charges 0.19%.
Who manages BBH?
BBH is offered by VanEck through VanEck ETF Trust.